Abstracts tagged "giant cell arteritis"

Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 1924 • ACR Convergence 2020
Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
John H. Stone¹, Navita L. Mallalieu² and Min Bao³, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Innovation Center, New York, NY, ³Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) has low immunogenicity in patients with rheumatoid arthritis (RA).1 The risk for TCZ immunogenicity remains to be determined in patients with giant…
Abstract Number: 1942 • ACR Convergence 2020
Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Lara Burg¹, Peter Brossart², Charlotte Behning³ and Valentin Schaefer⁴, ¹Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) often coexist.1 The role of modern ultrasound (US) in diagnosis of GCA as well as PMR…
Abstract Number: 0515 • ACR Convergence 2020
A Proof of Concept Study to Assess the Efficacy of Tocilizumab in Combination with Ultra-Short Glucocorticoid Administration to Treat Newly Diagnosed Giant Cell Arteritis – a 24 Week Analysis
Lisa Christ¹, Luca Seitz¹, Lukas Buetikofer², Godehard Scholz¹, Adela-Cristina Sarbu¹, Jennifer Amsler¹, Florian Kollert¹, Stephan Reichenbach¹ and Peter Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ²Clinical Trials Unit, University of Bern, Bern, Switzerland, Bern, Switzerland
Background/Purpose: Two randomized controlled trials [Villiger et al. Lancet 2016; Stone et al. NEJM 2017] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at…
Abstract Number: 1926 • ACR Convergence 2020
Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial
John H. Stone¹, Jian Han² and Shalini V. Mohan², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: There is conflicting evidence for methotrexate (MTX) efficacy in giant cell arteritis (GCA).1,2 Subanalysis of data from the 52-week, double-blind, randomized controlled GiACTA trial…
Abstract Number: 1943 • ACR Convergence 2020
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis of the elderly causing blindness if left untreated. However, its hallmark treatment with glucocorticoids…
Abstract Number: 0516 • ACR Convergence 2020
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
Sebastian Unizony¹, Shalini V. Mohan², Jian Han² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
Abstract Number: 1927 • ACR Convergence 2020
Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA
Alwin Sebastian¹, Abdul Kayani¹, Sue Innes², Jo Jackson², Kornelis S. M. van der Geest³ and Bhaskar Dasgupta¹, ¹Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ²School of Sport, Rehabilitation and Exercise science, Colchester Campus, University of Essex, United Kingdom, Colchester, England, United Kingdom, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Netherlands, Groningen, Netherlands
Background/Purpose: EULAR recommendations highlights ultrasound (US) as the first line imaging investigation for giant cell arteritis (GCA). Traditionally, the halo sign and compression sign have…
Abstract Number: 1944 • ACR Convergence 2020
Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis
Ana Rita Cruz-Machado¹, Sofia Barreira², Eduardo Dourado³, Joana Martinho¹, Diana Raimundo⁴, Luísa Brites⁵, Helena Assunção⁵, Vítor Teixeira⁶, Nikita Khmelinskii¹, Carla Macieira¹, José A. P. da Silva⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário Coimbra, Coimbra, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis in patients (pts) aged over 50 years. It is a medical emergency due to…
Abstract Number: 1837 • 2019 ACR/ARP Annual Meeting
Ustekinumab for the Treatment of Giant Cell Arteritis
Mark Matza¹, John Stone ¹, Ana Fernandes ¹ and Sebastian Unizony ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Disease flare despite high cumulative glucocorticoid exposure is one of the hallmarks of giant cell arteritis (GCA). Tocilizumab is effective in controlling disease activity…
Abstract Number: 2664 • 2019 ACR/ARP Annual Meeting
Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience
Jean-Paul Makhzoum¹, Meriem Belhocine ¹, Michelle Goulet ¹, Maxime Rheaume ¹, Tara Starnino ², Stephanie Ducharme-Benard ², Guillaume Febrer ³, Yves Troyanov ⁴, Nathalie Routhier ⁵, Rosalie-Selene Meunier ⁵, Isabelle Chagnon ⁵, Michel Laurier ⁵, Maggy Helou ⁵, Nathalie Morency ⁶ and Anne-Marie Mansour ¹, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ³Vascular Surgery, Department of Surgery, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Internal Medicine, Department of Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁶Division of Rheumatology, Department of Medicine, Montreal, Canada
Background/Purpose: Giant Cell Arteritis (GCA) remains challenging to diagnose as false negative temporal artery biopsy (TAB) can occur. Color doppler ultrasonography (CDUS) of the temporal,…
Abstract Number: 2688 • 2019 ACR/ARP Annual Meeting
Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Raashid Luqmani ³, Richard Watts ⁶, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Diagnostic assessment in giant cell arteritis (GCA) is rapidly changing as large-vessel (LV) involvement becomes increasingly recognized and non-invasive vascular imaging techniques become more…
Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Hubert de BOYSSON¹, Eric LIOZON ², Olivier ESPITIA ³, Aurélie DAUMAS ⁴, Mathieu VAUTIER ⁵, Marc LAMBERT ⁶, Jean-Jacques PARIENTI ⁷, Alain MANRIQUE ⁷, David Saadoun ⁸, Kim Heang Ly ², Christian Agard ⁹ and Achille Aouba ¹⁰, ¹University Hospital of Caen, Caen, France, ²Limoges University Hospital, Limoges, France, ³Nantes University Hospital, Nantes, France, ⁴Marseille AP-HM, Marseille, France, ⁵Paris - Pitié salpétrière, Paris, France, ⁶Lille University Hospital, Lille, France, ⁷Caen University Hospital, Caen, France, ⁸AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ⁹CHU Nantes, Nantes, France, ¹⁰CHU Caen, Caen, France
Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…
Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 2690 • 2019 ACR/ARP Annual Meeting
Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Ingeborg Sacksen ¹, Elizabeth Jernberg ¹, Scott Pollock ², Jean Liew ³, Sarah Chung ², R Eugene Zierler ³ and Alison Bays², ¹University of Washington Division of Rheumatology, Seattle, ²University of Washington Division of Rheumatology, Seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults and if untreated, may result in visual impairment. Although the gold…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].